Re: Chemotherapy-related myelosuppression as a marker for survival in epithelial ovarian cancer patients by Rocconi et al.
Author:
- 31 October 2008
- journal article
- other
- Published by Elsevier in Gynecologic Oncology
- Vol. 111 (1) , 159-160
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patientsGynecologic Oncology, 2008
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI: Journal of the National Cancer Institute, 2004
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003